Leaked Emails Reveal Corporate kratom Influence Shaping Federal Regulators on 7-OH Policy

For years, the kratom community in the United States has portrayed itself as a grassroots coalition of small businesses, consumer advocates, and scientists pushing for responsible regulation and harm reduction. But newly leaked internal emails and documents paint a very different picture—one driven more by strategic influence than public health priorities. These communications suggest that some within the industry used behind-the-scenes access to federal regulators to shape enforcement actions against products like 7-hydroxymitragynine, or 7-OH.

Rather than responding to clear safety risks or emerging toxicology data, these actions appear motivated by competitive market dynamics. Some industry insiders felt threatened by the growing popularity of 7-OH, which offers enhanced pain relief properties for some patients. Instead of innovating or educating, they opted to influence regulators directly—pressuring agencies like the FDA and DEA to target 7-OH products.

According to emails reviewed by investigative reporters at The National Pulse, a group of consultants and industry representatives arranged a private meeting in early 2025 with enforcement attorneys and investigators at the Food and Drug Administration. The meeting wasn’t focused on scientific review or policy consultation. It was an enforcement strategy session aimed at removing 7-OH products from the U.S. market.

Federal scientists from leading institutions like Johns Hopkins and Harvard declined to participate, citing concerns that the meeting lacked scientific neutrality. Instead of providing data for unbiased evaluation, participants reportedly focused on criminal histories and regulatory messaging, creating an enforcement narrative around 7-OH that felt more like market manipulation than public health protection.

The story doesn’t end there. Documents show that academic research was also leveraged to influence the regulatory narrative. One university lab, Dr. Christopher McCurdy at the University of Florida, became a key reference point in federal agency communications. Researchers from the lab coordinated with both FDA and DEA officials and were cited as independent voices—even though some of the research was funded by industry groups with a clear stake in how 7-OH was portrayed.

In one striking example, kratom plant material was routed through a university lab from Malaysia in ways that circumvented export restrictions. This material was then used in research that ultimately became part of the justification for federal regulatory action. While positioned as academic science, the research pipeline was initiated and influenced by private interests.

Shortly after these meetings and research efforts, media narratives began to shift. Articles warning about 7-OH as a dangerous synthetic compound circulated widely. Some states proposed new legislative restrictions. Enforcement escalated. But all of this happened in the absence of large-scale toxicological evidence suggesting widespread harm from 7-OH itself. The public story had changed—but the scientific foundation remained shaky.

So why does this matter?

First, it raises questions about whether federal regulation is truly based on science or simply shaped by whoever has access and influence. If enforcement priorities are being set by private actors trying to eliminate competition, we lose trust in the regulatory process. Second, products like 7-OH—which may offer unique value to chronic pain patients, especially those transitioning off opioids—deserve fair, evidence-based evaluation. Shutting down access without adequate research means potentially depriving patients of plant-based tools that work for them.

Finally, these revelations matter because the kratom and 7-OH communities rely on integrity. Brands, healthcare providers, and patients need to know that what’s being regulated—or banned—is grounded in unbiased science, not political favoritism or commercial fear.

As we look ahead, the path forward is clear. We need open science, transparent policy conversations, and an end to backroom deals that put industry interests ahead of patient safety. If we want kratom and 7-OH to have a future, it must be built on truth—not tactics.